CSBR
CHAMPIONS ONCOLOGY, INC.
-0.01 (-0.22%)4.94USD18.8K成交股數68.7M市值–本益比(近四季)1.1股價營收比+8.8%營收年增(近四季)2026-09-10下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 4 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 15.2M+9% | 13.8M-19% | 16.6M+23% | 15.0M+7% | 14.0M-0% | 17.0M+42% | 13.5M+17% | 14.1M+12% | 14.0M | 12.0M | 11.6M | 12.6M |
| 營業成本 | 7.5M | 6.8M | 8.8M | 7.3M | 8.0M | 6.6M | 7.4M | 7.1M | 7.3M | 7.8M | 6.6M | 7.7M |
| 毛利 | 7.7M+28% | 7.0M-33% | 7.7M+27% | 7.8M+11% | 6.0M-11% | 10.4M+150% | 6.1M+22% | 7.0M+43% | 6.8M | 4.2M | 5.0M | 4.9M |
| 毛利率 | 50.5% | 50.8% | 46.7% | 51.7% | 42.9% | 61.2% | 44.9% | 49.7% | 48.2% | 34.7% | 42.8% | 38.8% |
| 研發費用 | 2.3M | 2.1M | 2.3M | 2.6M | 2.1M | 1.7M | 1.7M | 1.5M | 2.1M | 2.2M | 2.5M | 2.8M |
| 銷售管理費用 | 2.7M | 2.6M | 3.0M | 3.0M | 2.6M | 2.4M | 1.9M | 2.5M | 2.8M | 2.8M | 2.6M | 2.9M |
| 營業利益 | −409K-22% | −522K-112% | −276K-138% | 185K-86% | −527K+94% | 4.5M-275% | 732K-137% | 1.3M-152% | −272K | −2.6M | −2.0M | −2.6M |
| 營業利益率 | -2.7% | -3.8% | -1.7% | 1.2% | -3.8% | 26.4% | 5.4% | 9.5% | -1.9% | -21.4% | -16.9% | -20.3% |
| 稅後淨利 | −426K-9% | 476K-89% | −279K-138% | 268K-80% | −466K-107% | 4.5M-278% | 728K-135% | 1.3M-151% | 7.2M | −2.5M | −2.1M | −2.6M |
| 淨利率 | -2.8% | 3.4% | -1.7% | 1.8% | -3.3% | 26.4% | 5.4% | 9.3% | 51.1% | -21.1% | -17.9% | -20.4% |
| 稀釋 EPS | – | -0.05-116% | -0.02-140% | 0.02-78% | -0.03+200% | 0.31-263% | 0.05-133% | 0.09-147% | -0.01 | -0.19 | -0.15 | -0.19 |
| 稀釋股數 | – | 13.8M | 13.9M | 14.5M | 13.8M | 14.4M | 14.0M | 14.0M | 13.5M | 13.6M | 13.5M | 13.5M |
資產負債表 期末餘額
| 科目 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 4.4M | 4.9M | 7.1M | 8.5M | 10.3M | 3.2M | 2.8M | 2.9M | 2.6M | 4.5M | 5.5M | 4.9M |
| 應收帳款 | 13.6M | 13.2M | 12.1M | 11.5M | 9.5M | 15.8M | 10.5M | 9.0M | 9.5M | 7.9M | 7.7M | 9.0M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 33.3M | 27.0M | 28.4M | 30.2M | 30.5M | 30.6M | 25.2M | 24.9M | 26.1M | 26.8M | 28.3M | 29.9M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 28.8M | 22.9M | 24.1M | 25.9M | 27.0M | 25.2M | 24.6M | 25.3M | 28.0M | 28.8M | 28.2M | 28.0M |
| 股東權益 | 3.9M | 3.9M | 4.3M | 4.2M | 3.5M | 5.5M | 681K | −332K | −1.9M | −2.1M | 93K | 1.9M |
| 負債比 | 86.6% | 84.9% | 84.6% | 86.0% | 88.4% | 82.1% | 97.3% | 101.3% | 107.3% | 107.7% | 99.7% | 93.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | −492K-182% | – | – | – | 600K | – | – | 311K-108% | – | – | – | −4.0M |
| 資本支出 | 55K | – | – | – | 46K | – | – | 0 | – | – | – | 668K |
| 自由現金流 | −547K-199% | – | – | – | 554K | – | – | 311K-107% | – | – | – | −4.7M |
| 折舊攤銷 | 314K | 344K | 341K | 357K | 358K | 398K | 399K | 449K | 490K | 481K | 484K | 445K |
| 買回庫藏股 | – | – | – | – | – | – | – | 0 | – | – | – | 602K |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | -3.6% | – | – | – | 4.0% | – | – | 2.2% | – | – | – | -37.1% |
營收拆解 2026 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2026 年度 · 59.4M
| Pharmacology Services | 57.1M | 96.1% | +17.6% |
|---|---|---|---|
| Product And Service Other | 1.5M | 2.6% | -58.5% |
| Translational Oncology Solutions TOS License Revenue | 764K | 1.3% | -83.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2026 | 59.4M | +4.4% | −1K | -0.0% | -0.08 | −5.0M |
| FY2025 | 56.9M | +13.5% | 5K | 0.0% | 0.33 | 7.0M |
| FY2024 | 50.2M | -6.9% | −7K | -0.0% | -0.54 | −7.0M |
| FY2023 | 53.9M | +9.7% | −5.3M | -9.9% | -0.39 | 1.1M |
| FY2022 | 49.1M | +19.7% | 548K | 1.1% | 0.04 | 4.1M |
| FY2021 | 41.0M | +27.8% | 362K | 0.9% | 0.02 | −5.0M |
| FY2020 | 32.1M | +18.7% | −2.1M | -6.5% | -0.18 | 685K |
| FY2019 | 27.1M | – | 128K | 0.5% | 0.01 | 1.0M |